-Reuters
RBC Capital Maintains Outperform on Rapid7, Raises Price Target to $60
RBC Capital analyst Matthew Hedberg maintains Rapid7 (NASDAQ:RPD) with a Outperform and raises the price target from $47 to $60.
Related Posts
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat advanced forms of endometrial cancer with mismatch repair deficiency. This critical approval is based on Phase III trial results showing a 58% reduction in disease progression, promising improved outcomes for those battling this severe cancer.
Rivian, Marathon Digital, Twilio, Tesla, Celsius: Why These Five Stocks Are Drawing Investors’ Attention Today
U.S. stocks ended Tuesday in the red, with the Dow Jones falling over 100 points. The Dow traded down 0.45% to 35,314.49 while the NASDAQ fell 0.79% to 13,884.32. The S&P 500 also experienced a decline, dropping 0.42% to 4,499.38.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Inuvo Enhances its AI-Generated IntentKey Insights Dashboard For Clients
Inuvo, Inc. (NYSE:INUV), a leading provider of marketing technology, powered by artificial intelligence (AI) that serves brands and agencies, announced today the launch of its enhanced IntentKey Insights